VIDEO: Novel therapies for intermediate AMD, Stargardt disease raise hope
Click Here to Manage Email Alerts
ROME — In this Healio Video Perspective from the FLORetina-ICOOR meeting, Quan Dong Nguyen, MD, MSc, shares the latest achievements in two areas: intermediate age-related macular degeneration and Stargardt disease.
In patients with intermediate non-neovascular AMD, treatment with photobiomodulation (LumiThera) over a 2-year period showed visual acuity improvement, decreasing the risk of progressing to wet AMD or geographic atrophy.
Stargardt disease is a devastating condition with no treatment. The use of a new drug, tinlarebant (LBS-008, Belite Bio), has demonstrated promising results in children younger than 18 years old and is currently under investigation in the phase 3 DRAGON study.
“We are waiting on the patients who have been followed throughout the world to see whether or not we will have the first treatment for patients with Stargardt disease,” Nguyen said.
References:
- Nguyen QD. Photobiomodulation for non-neovascular AMD: Outcomes of the LIGHTSITE III Study. Presented at: FLORetina-ICOOR; Nov. 30-Dec. 3, 2023; Rome.
- Nguyen QD. Tinlarebant (LBS-008) in adolescent subjects with Stargardt disease: The story continues. Presented at: FLORetina-ICOOR; Nov. 30-Dec. 3, 2023; Rome.
Collapse
Healio Interviews
Read more about
Click Here to Manage Email Alerts